...
首页> 外文期刊>International journal of laboratory hematology >Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield
【24h】

Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield

机译:使用自动血液学分析仪进行造血祖细胞计数的预测值,用于CD34 +干细胞动员和血液化产物产量

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Introduction We evaluated the value of hematopoietic progenitor cells (HPCs) counted in Sysmex XN analyzers to predict the mobilization and collection of CD34+ cells in apheresis for stem cell transplantation. Methods Eighty patients who underwent stem cell transplantation were enrolled (50 autologous and 30 allogeneic). In the autologous group, patients were considered poor mobilizers when the CD34+ count was 10?×?10 6 /L or 20?×?10 6 /L in patients with multiple myeloma who were going to undergo two transplants. ROC curves were generated, and HPC cutoffs were calculated. Results The correlation between the HPC and CD34+ cell counts was good. Two algorithms were proposed. In the first algorithm, samples collected the day before apheresis, negative and positive HPC cutoffs were selected to detect poor and good mobilization and, therefore, the need or not to administer plerixafor. In the second algorithm, samples collected pre‐apheresis, the negative HPC cutoff was an indication to delay apheresis; an HPC higher than the optimal cutoff was an indication to start apheresis. When the HPC values were between these cutoffs, there was an indication to count CD34+ cells for a better decision‐making. Finally, in samples collected pre‐apheresis, HPC counts could be used to predict patients who would have poor CD34+ cell collections. In the allogeneic group, all the donors mobilized well, and very few needed two apheresis procedures. Conclusions The HPC count is useful for decision‐making in the management of patients subjected to apheresis procedures to collect peripheral blood stem cells.
机译:摘要介绍我们评估了在Sysmex XN分析仪中计算的造血祖细胞(HPC)的价值预测干细胞移植的血液吸入中CD34 +细胞的动员和收集。方法纳入干细胞移植的80例患者(50个自体和30个同种异体)。在自体组中,当CD34 +计数是患者的患者时,患者被认为是较差的动员器,其中多个骨髓瘤的多发性骨髓瘤的患者中的患者。产生了ROC曲线,并计算了HPC截止值。结果HPC和CD34 +细胞计数之间的相关性好。提出了两种算法。在第一种算法中,选择采集前一天的样品,选择阴性和阳性HPC截止值,以检测较差和良好的动员,因此需要或不给施用Plerixafor。在第二种算法中,采样收集的预洗涤物,负HPC截止值为延迟容易凋亡;高于最佳截止的HPC是启动容纳筛查的指示。当HPC值在这些截止之间时,有一个指示CD34 +电池以获得更好的决策。最后,在收集预洗析性的样品中,HPC计数可用于预测具有差的CD34 +细胞收集的患者。在同种异体群体中,所有的捐助者都会迅速调动,并且很少需要两个采集程序。结论HPC计数对于患者进行患者的决策,可用于收集外周血干细胞的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号